Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy
Yıl: 2018 Cilt: 22 Sayı: 3 Sayfa Aralığı: 145 - 150 Metin Dili: İngilizce DOI: 10.25179/tjem.2018-59939 İndeks Tarihi: 13-11-2018
Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy
Öz: Objective: Diabetic nephropathy is a frequent complication of diabetes mellitus and is a common cause of the end-stage renal disease. Diabetic nephropathy should be detected and treated at the early microalbuminuria stage, which is potentially reversible. Microalbuminuria used as a gold standard to determine the degree of advancement of diabetic nephropathy has certain limitations; hence, additional markers are being sought for the early identification of diabetic complications. Ischemia-modified albumin, an oxidative stress marker, has been shown to be associated with diabetic complications. The aim of the study: The present study is undertaken to evaluate ischemia-modified albumin as a useful marker in estimating kidney dysfunction in patients with diabetic nephropathy along with urine microalbumin and creatinine. Material and Methods: This was a case-control study that enrolled 40 patients with diabetic nephropathy and 40 age and gender-matched controls. All biochemical parameters were analyzed on a Beckman Coulter Unicel DXC 600 clinical chemistry auto analyzer, Galway, Ireland. Ischemia-modified albumin was estimated by the albumin cobalt binding test using a Perkin Elmer Lambda 25 spectrophotometer. Results: Compared with controls, urine microalbumin and ischemia-modified albumin levels were significantly increased in patients with diabetic nephropathy (p<0.001). Ischemia-modified albumin levels showed a significant positive correlation between creatinine and microalbumin in patients with diabetic nephropathy. Ischemia-modified albumin showed the high sensitivity of 92.5% and specificity of 97.5% than microalbumin did. Conclusion: The results suggest that simultaneous measurement of ischemia-modified albumin with other parameters such as creatinine and microalbumin might be useful in identifying early kidney dysfunction in patients with diabetes mellitus.
Anahtar Kelime: Konular:
Diyabetik Nefropatili Hastalarda İskemi Modifiye Albumin Düzeyleri
Öz: Amaç: Diyabetik nefropati; diyabetin sık görülen bir komplikasyonu olup, son dönem böbrek hastalığının en sık nedenidir. Diyabetik nefropati geri dönüşümlü olabildiği erken mikroalbuminüri evresinde tespit ve tedavi edilmelidir. DN derecesini tespit etmede altın standart olarak kullanılan mikroalbüminürinin bazı kısıtlamaları olmasından dolayı diyabetik komplikasyonların erken tanınması için ek belirteçler aranmaktadır. Bir oksidatif stres belirteci olan iskemi modifiye albüminin diyabetik komplikasyonlarla ilişkili olduğu gösterilmiştir. Bu çalışma, diyabetik nefropati olan hastalarda böbrek fonksiyon bozukluğunun tahmini için iskemi modifiye albüminin idrarda mikroalbümin ve kreatinin ile birlikte faydalı bir belirteç olup olmadığını değerlendirmek için gerçekleştirilmiştir. Gereç ve Yöntemler: Bu vaka-kontrol çalışmasına, 40 DN hastası ile yaş ve cinsiyet açısından eşleşen 40 sağlıklı kontrol alınmıştır. Tüm biyokimyasal parametreler Beckman Coulter Unicel DXC 600, Galway, İrlanda marka klinik kimya oto analizörü kullanılarak analiz edilmiştir. IMA tahmini, Perkin Elmer Lambda 25 spektrofotometre kullanılarak albümin kobalt bağlayıcı test ile yapılmıştır. Bulgular: Kontrollerle kıyaslandığında, diyabetik nefropati hastalarında idrar mikroalbümin ve iskemi modifiye albümin düzeylerinin anlamlı olarak yükseldiği gözlenmiştir (p<0.001). Diyabetik nefropati hastalarında iskemi modifiye albümin düzeyleri ile kreatinin ve mikroalbümin arasında anlamlı pozitif korrelasyon gözlendi. Mikroalbümine kıyasla iskemi modifiye albümin daha yüksek duyarlılık ve özgüllüğe sahip idi (sırasıyla %92,5 ve %97,5). Sonuç: Sonuçlar, iskemi modifiye albümin değerlerinin kreatinin ve mikroalbümin gibi diğer parametrelerle eş zamanlı ölçümünün diabetes mellitus hastalarında erken böbrek fonksiyon bozukluklarının belirlenmesinde faydalı olabileceğini göstermiştir.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Dahiya K, Kumawat M, Kaur R, Yadav S, Singh J, Ghalaut VS, Dhankhar R. Ischemia modified albumin and nitric oxide in diabetic nephropathy. J Diabetol. 2017;157:167.
- Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17:24-38.
- Bilgi M, Keser A, Katlandur H, Sahin E, Kalkan AO, Yildiz M, Kiyici A, Keles M. Evaluation of the relationship between microalbuminuria and urine ischemia-modified albumin levels in patients with diabetic nephropathy. J Clin Lab Anal. 2017;31:4- 6.
- Kumawat M, Pahwa MB, Gahlaut VS, Singh N. Status of antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus with micro vascular complications. The Open Endocrinology Journal. 2009;3:12-15.
- Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;11:4- 9.
- Dash P, Mangaraj M, Ray S. Physiobiochemical metabolism ischaemia modified albumin-an indicator of widespread endothelial damage in diabetes. J Physiobio¬chem Metab. 2014;3:1.
- Borderie D, Allanore Y, Meune C, Devaux JY, Ekindjian OG, Kahan A. High ischemia-modified albumin concentration reflects oxidative stress but not myo¬cardial involvement in systemic sclerosis. Clin Chem. 2004;50:2190-2193.
- Ma SG, Wei CL, Hong B, Yu WN. Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo). 2011;66:1677-1680.
- Dahiya K, Aggarwal K, Seth S, Singh V, Sharma TK. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin. Clin Lab. 2010;56:187-190.
- Kotani K, Kimura S, Kinugasa E, Ogata H, Caccavello R, Taniguchi N, Gugliucci A. Correlation between ischaemia-modified albumin and intermediate-density lipoprotein in haemodialysis patients with end-stage renal disease. J Int Med Res. 2011;39:1541-1545.
- Ukinc K, Eminagaoglu S, Ersoz HO, Erem C, Karahan C, Hacihsanoglu ABi, Kocak M. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine. 2009;36:425-432.
- Piwowar A, Kordecka MK, Warwas M. Connection between ischemia-modified albumin levels and markers of diabetic nephropathy and oxidative protein dam¬age in type 2 diabetic patients. Adv Clin Exp Med. 2009;18:353-360.
- Piwowar A, Knapik- Kordecka M, Warwas M. Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients. Clin Invest Med. 2010;33:E109.
- Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin levels in type 2 diabetes mellitus- preliminary report. Dis Markers. 2008;24: 311-317.
- Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000;19:311-315.
- Jafar TH, Chaturvedi N, Hatcher J, Levey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant. 2007;22:2194-2200.
- Harmoinen A, Vuorinen P, Jokela H. Turbidimetric measurement of microalbuminuria. Clin Chim Acta. 1987;166:85-89.
- Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus-preliminary report. Dis Markers. 2008;24: 311-317.
- Vaishya R, Arora S, Singh B, Mallika V. Modification of Jaffe’s kinetic method decreases bilirubin interference: a preliminary report. Indian J Clin Biochem. 2010;25:64-66.
- Abboud H, Labreuche J, Mesequer E, Lavallee PC, Simon O, Olivot JM, Mazighi M, Dehoux M, Benessiano J, Steg PG, Amarenco P. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis. 2007;23: 216-220.
- Ma SG, Jin Y, Hu W, Bai F, Xu W, Yu WN. Evaluation of ischemia-modified albumin and C reactive protein in type 2 diabetics with and without ketosis. Biomark Insights. 2012;7:19-26.
- Singh DK, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol. 2011;7:176-184.
- Kim SS, Song SH, Kim IJ, Yang JY, Lee JG, Kwak IS, Kim YK. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract. 2012;97: 251-257.
- Fiseha T. Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. Biomark Res. 2015;3:16.
- Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study. Diabetes. 2006;55:1832- 1839.
- Moresco RN, Sangoi MB, De Carvalho JA, Tatsch E, Bochi GV. Diabetic neph-ropathy: traditional to proteomic markers. Clin Chim Acta. 2013;421:17- 30.
- Piwowar A, Kordecka MK, Warwas M. Connection between ischemia-modified albumin levels and markers of diabetic nephropathy and oxidative protein dam¬age in type 2 diabetic patients. Adv Clin Exp Med. 2009;18:353-360.
| APA | BHASKHAR K, DEVİ N H, BITLA A, RAO PVLN S, KUMAR V. S, SACHAN B A (2018). Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. , 145 - 150. 10.25179/tjem.2018-59939 |
| Chicago | BHASKHAR K. Udaya,DEVİ N Harini,BITLA Aparna R.,RAO PVLN Srinivasa,KUMAR V. Siva,SACHAN B Alok Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. (2018): 145 - 150. 10.25179/tjem.2018-59939 |
| MLA | BHASKHAR K. Udaya,DEVİ N Harini,BITLA Aparna R.,RAO PVLN Srinivasa,KUMAR V. Siva,SACHAN B Alok Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. , 2018, ss.145 - 150. 10.25179/tjem.2018-59939 |
| AMA | BHASKHAR K,DEVİ N H,BITLA A,RAO PVLN S,KUMAR V. S,SACHAN B A Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. . 2018; 145 - 150. 10.25179/tjem.2018-59939 |
| Vancouver | BHASKHAR K,DEVİ N H,BITLA A,RAO PVLN S,KUMAR V. S,SACHAN B A Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. . 2018; 145 - 150. 10.25179/tjem.2018-59939 |
| IEEE | BHASKHAR K,DEVİ N H,BITLA A,RAO PVLN S,KUMAR V. S,SACHAN B A "Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy." , ss.145 - 150, 2018. 10.25179/tjem.2018-59939 |
| ISNAD | BHASKHAR, K. Udaya vd. "Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy". (2018), 145-150. https://doi.org/10.25179/tjem.2018-59939 |
| APA | BHASKHAR K, DEVİ N H, BITLA A, RAO PVLN S, KUMAR V. S, SACHAN B A (2018). Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. Turkish Journal of Endocrinology and Metabolism, 22(3), 145 - 150. 10.25179/tjem.2018-59939 |
| Chicago | BHASKHAR K. Udaya,DEVİ N Harini,BITLA Aparna R.,RAO PVLN Srinivasa,KUMAR V. Siva,SACHAN B Alok Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. Turkish Journal of Endocrinology and Metabolism 22, no.3 (2018): 145 - 150. 10.25179/tjem.2018-59939 |
| MLA | BHASKHAR K. Udaya,DEVİ N Harini,BITLA Aparna R.,RAO PVLN Srinivasa,KUMAR V. Siva,SACHAN B Alok Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. Turkish Journal of Endocrinology and Metabolism, vol.22, no.3, 2018, ss.145 - 150. 10.25179/tjem.2018-59939 |
| AMA | BHASKHAR K,DEVİ N H,BITLA A,RAO PVLN S,KUMAR V. S,SACHAN B A Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. Turkish Journal of Endocrinology and Metabolism. 2018; 22(3): 145 - 150. 10.25179/tjem.2018-59939 |
| Vancouver | BHASKHAR K,DEVİ N H,BITLA A,RAO PVLN S,KUMAR V. S,SACHAN B A Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy. Turkish Journal of Endocrinology and Metabolism. 2018; 22(3): 145 - 150. 10.25179/tjem.2018-59939 |
| IEEE | BHASKHAR K,DEVİ N H,BITLA A,RAO PVLN S,KUMAR V. S,SACHAN B A "Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy." Turkish Journal of Endocrinology and Metabolism, 22, ss.145 - 150, 2018. 10.25179/tjem.2018-59939 |
| ISNAD | BHASKHAR, K. Udaya vd. "Ischemia Modified Albumin Levels in Patients with Diabetic Nephropathy". Turkish Journal of Endocrinology and Metabolism 22/3 (2018), 145-150. https://doi.org/10.25179/tjem.2018-59939 |
